PCSK9
Proprotein Convertase Subtilisin/Kexin type 9, a gene involved in cholesterol production that could be edited to permanently lower cholesterol.
As defined in How to Be a Super Ager (with Eric Topol)
Where it comes up · 4
- Zach Reitano - Building Ro and Why Healthcare Should Be 50% of GDP - [Invest Like the Best, EP.500]3 claims
- Alex Karnal - The Trillion-Dollar Health Revolution - [Invest Like the Best, EP.468]2 claims
- 112 | Fyodor Urnov on Gene Editing, CRISPR, and Human Engineering2 claims
- How to Be a Super Ager (with Eric Topol)1 claim
Most important claims · 8 of 8Search all claims for “PCSK9” →
- The Dallas Heart Study found people with a faulty PCSK9 gene had LDL in the 30s to 40s and an 85 to 90 percent lower risk of heart disease regardless of lifestyle; from the 2006 finding to the 2026 oral PCSK9 approval took about two decades, which Reitano sees as too long.Zach Reitano - Building Ro and Why Healthcare Should Be 50% of GDP - [Invest Like the Best, EP.500]
- AI excels where data is structured, rewards are verifiable, and feedback loops are tight, as in math and coding, but medicine is trial and error with unstructured data and feedback that takes years, such as death or heart disease.Zach Reitano - Building Ro and Why Healthcare Should Be 50% of GDP - [Invest Like the Best, EP.500]
- Rare individuals lacking a normal copy of PCSK9 have vanishingly low heart-attack risk yet are otherwise fine, so active efforts—with clinical trials possibly starting as early as 2022—aim to prospectively delete this gene in people at severe cardiovascular risk before they suffer a heart attack.112 | Fyodor Urnov on Gene Editing, CRISPR, and Human Engineering
- Within the next five to ten years, gene editing will deliver dramatic advances—more cures for certain cancers via editing the immune system, substantial reduction of the burden of sickle cell disease and hemophilia, non-addictive treatment of chronic pain by editing pain or endocannabinoid genes, and prevention of heart attacks by deleting PCSK9—though prediction beyond ten years is impossible because future technologies are unknowable.112 | Fyodor Urnov on Gene Editing, CRISPR, and Human Engineering
- PCSK9 medicines lower bad cholesterol by about 50 percent, cut heart attack and stroke risk by over 20 percent in previously affected patients, and by about 25 percent in high-risk patients.Alex Karnal - The Trillion-Dollar Health Revolution - [Invest Like the Best, EP.468]
- When Repatha went direct-to-consumer, its price fell from about $600 a month to about $200, a 60 to 70 percent reduction.Zach Reitano - Building Ro and Why Healthcare Should Be 50% of GDP - [Invest Like the Best, EP.500]
- Somatic genome editing is much bigger than rare-disease treatment because some rare-disease genes share threads with common diseases: editing PCSK9 could permanently slash cholesterol so people never need statins, and editing APOE-4 to the favorable APOE-2 allele could reduce Alzheimer's risk, with potential application even to the gut microbiome.How to Be a Super Ager (with Eric Topol)
- PCSK9 and LDL management suffer from lower adherence than GLP-1s because high LDL produces no felt symptoms, so patients fail to stay on drugs that protect them.Alex Karnal - The Trillion-Dollar Health Revolution - [Invest Like the Best, EP.468]